GENE ONLINE|News &
Eisai Unveils Lecanemab Data Following Reports of Second Alzheimer’s Patient Death
Before the FDA’s upcoming approval decision for Eisai’s Alzheimer’s treatment, lecanemab, the company released Phase 3 study data from the confirmatory CLARITY AD trial. The release comes just days after reports of a second patient death in the trial, which Eisai addressed, saying both deaths resulted from substantial comorbidities and risk factors, not from lecanemab.
It's free! Log in now to read
LATEST
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
